Neurology Central

Novartis to seek US approval of siponimod for SPMS: industry news round up

Clinical trial announcements, orphan-drug designation and more: check out our round-up of the biggest news from the neuroscience and neurology industries this week.
Our pick of the highlights include:
  • Rimegepant successfully achieves primary endpoints in two Phase III trials for migraine
  • Novartis to seek US approval of siponimod in patients with SPMS
  • Constant Pharmaceuticals announces European patent issuance for TXA127 in stroke treatment
  • GeneTx Biotherapeutics receives US FDA orphan-drug designation for Angelman syndrome
    Restricted Content / Members Only

    You cannot view this content because It is available to members only. Please or Register to view this area.